You are here: Industry Insights > avelumab

News List

SMC approves Bavencio for bladder cancer pharmatimes
August 11, 2021
Merck and Pfizer’s Bavencio (avelumab) has been approved by the Scottish Medicines Consortium (SMC) for use via NHS Scotland as a first-line maintenance treatment for adult patients with locally advanced or metastatic urothelial carcinoma ...
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study prnasia
March 10, 2021
Genome and Company, a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA, Darmstadt, Germany and Pfizer Inc. with the aim of developing the world's ...
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 25, 2021
Merck and Pfizer Inc. today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are ...
Avelumab significantly improves advanced bladder cancer patient survival europeanpharmaceuticalreview
September 22, 2020
A Phase III trial concluded that avelumab is an effective maintenance therapy for patients with advanced or metastatic urothelial carcinoma, whose disease had not progressed after chemotherapy.
NKMax America Partners with Merck KGaA and Pfizer contractpharma
September 18, 2020
Will evaluate the safety and tolerability of SNK01 in combination with avelumab (BAVENCIO).
NICE recommends avelumab and axitinib to treat renal cell carcinoma europeanpharmaceuticalreview
August 03, 2020
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
FDA Approves Urothelial Carcinoma Maintenance Treatment americanpharmaceuticalreview
July 13, 2020
The U.S. Food and Drug Administration (FDA) approved avelumab (BAVENCIO, EMD Serono) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) ...
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma drugs
May 17, 2019
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma.
Merck KGaA, Pfizer added to BioXcel’s pancreatic cancer deal pharmatimes
March 06, 2019
BioXcel Therapeutics has announced the addition of Merck KGaA and Pfizer to clinical collaboration with Nektar Therapeutics, to evaluate a novel triple combination therapy in pancreatic cancer.
Merck, Pfizer Terminate Avelumab Trial of Previously Untreated Advanced Ovarian Cancer americanpharmaceuticalreview
December 27, 2018
Merck and Pfizer have announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab did not support the study's initial hypothesis.....

Previous page 1 2 3 Next page